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Abstract
Background—Combination of androgen ablation along with early detection and surgery has 
made prostate cancer highly treatable at the initial stage. However, this cancer remains the second 
leading cause of cancer death among American men due to castration-resistant progression, 
suggesting that novel therapeutic agents are urgently needed for this life-threaten condition. 
Phosphatidylinositol 3-kinase p110β is a major cellular signaling molecule and has been identified 
as a critical factor in prostate cancer progression. In a recent report, we established a nanomicelle-
based strategy to deliver p110β-specific inhibitor TGX221 to prostate cancer cells by conjugating 
the surface of nanomicelles with a RNA aptamer against prostate membrane specific antigen 
(PSMA) present in all clinical prostate cancers. In this study, we tested this nanomicellar TGX221 
for its in vivo anti-tumor effect in mouse xenograft models.
Methods—Prostate cancer cell lines LAPC-4, LNCaP, C4-2 and 22RV1 were used to establish 
subcutaneous xenograft tumors in nude mice. Paraffin sections from xenograft tumor specimens 
were used in immunohistochemistry assays to detect AKT phosphorylation, cell proliferation 
marker Ki67 and PCNA, as well as BrdU incorporation. Quantitative PCR assay was conducted to 
determine PSA gene expression in xenograft tumors.
Results—Although systemic delivery of unconjugated TGX221 significantly reduced xenograft 
tumor growth in nude mice compared to solvent control, the nanomicellar TGX221 conjugates 
completely blocked tumor growth of xenografts derived from multiple prostate cancer cell lines. 
Further analyses revealed that AKT phosphorylation and cell proliferation indexes were 
dramatically reduced in xenograft tumors received nanomicellar TGX221 compared to xenograft 
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tumors received unconjugated TGX221 treatment. There was no noticeable side effect by gross 
observation or at microscopic level of organ tissue section.
Conclusion—These data strongly suggest that prostate cancer cell-targeted nanomicellar 
TGX221 is an effective anti-cancer agent for prostate cancer.
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Introduction
The development of nano-scaled drug carriers is a prominent area of anti-cancer therapeutic 
development because these nano-scaled carriers can be easily modified to achieve tissue-
specific drug delivery and improved pharmacokinetics (1,2). Currently, various types of 
materials have been used to fabricate nano-scaled drug carriers, including polymeric, 
inorganic (e.g. quantum dots, carbon nanotubes, and gold nanoparticles) and nuclear acid 
(RNA and DNA molecules) materials (2-4). So far US FDA has approved several 
nanomedicines for clinical use (2).
Self-assembled core-shell nanocarriers (i.e. micelles) are capable of solubilizing a wide 
range of hydrophobic molecules (5) and are a potential tool for the safe formulation and 
delivery of antitumor agents to tumors without the inclusion of potentially harmful 
surfactants and excipients such as DMSO and propylene glycol (6). Due to their nanoscopic 
dimensions (< 100 nm), micelles can leave leaky vasculature, accumulating in tumors via 
the enhanced permeability and retention effect (EPR), where they remain due to poor 
lymphatic clearance. An outer coat of poly(ethylene glycol) (PEG) imparts “stealth” 
characteristics to micelles, allowing them to circulate for long periods of time and avoid 
accumulation in reticular endothelial system (RES) of the liver and spleen, as demonstrated 
in our previous reports (7-9). These effects potentially reduce non-specific toxicities by 
improving the drug's efficacy and enlarging the therapeutic window.
Phosphatidylinositol 3-kinases (PI3K) are a family of intracellular signaling molecules that 
regulate multiple signal pathways (10). There are three classes (I, II and III) of PI3K 
isoforms in mammalian cells, of which the class I PI3Ks p110α and p110β are ubiquitously 
expressed, and knocking out either one of these two genes in mice resulted in embryonic 
lethal (11). Recently, we discovered that p110β is expressed at a significantly higher level in 
prostate cancer tissues and cell lines compared to p110α and that p110β but not p110α is 
critical in androgen-stimulated cell proliferation, AR-mediated gene expression and 
xenograft tumor growth of xenografts derived from AR-positive prostate cancer cells in 
nude mice (12). We also determined that p110β expression is largely elevated in malignant 
prostate tissues compared to their surrounding non-malignant counterparts and its mRNA 
levels correlate with disease progression in prostate cancer patients (12). Our findings were 
supported by other groups using transgenic mouse models (13,14) and cell culture models 
(15). Taken together, these data indicate that targeting p110beta represents a potential 
therapeutic approach prostate cancer management.
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TGX-221 is a synthetic small molecule inhibitor and displays a wonderful isoform-
specificity towards p110β over other type IA PI3Ks (16). It has been successfully used in 
animal models to suppress p110β activity in vivo (17). However, TGX-221 is very poorly 
water soluble, requiring organic solvents such as DMSO and propylene glycol for 
intravenous injection, which have significant cardiac toxicity and may cause 
unconsciousness, arrhythmia, and cardiac arrest (18). Therefore, a cancer cell-targeted and 
water soluble formulation of this compound for human use is highly desirable. For this 
purpose, we recently synthesized a TGX221 analog BL05 that was encapsulated in a 
polymeric micelle (19). The surface of TGX221-BL05-loaded micelle was conjugated with 
a RNA aptamer against prostate membrane specific antigen (PSMA) present in all clinical 
prostate cancers (20). Our initial in vitro experiments demonstrated that PSMA aptamer-
conjugated nanomicellar TGX221 formulation has a 2.27-fold greater in the plasma 
concentration and a 6.16-fold slower in drug clearance rate than that of the naked drug in 
nude mice, suggesting a potential prostate cancer-targeted treatment. In this study, we 
evaluated the in vivo anti-tumor activity of the nanomicellar TGX221 formula in mouse 
xenograft tumor model of prostate cancer. Our data revealed that nanomicellar TGX221 
completely blocked xenograft tumor growth in nude mice derived from multiple prostate 
cancer cell lines. This drastic anti-tumor effect was associated with significant inhibition of 
AKT phosphorylation and cell proliferation in xenograft tumors.
Materials and Methods
Cell Culture, Antibodies and Reagents
Human prostate cancer LNCaP and 22RV1 cells were obtained from the American Type 
Culture Collection (Manassas, VA). C4-2 cell line was obtained from UroCor Inc 
(Oklahoma City, OK). LAPC-4 cells were from Dr. Charles L. Sawyers (21) and maintained 
in Iscoves medium with 15% FBS/1% L-glutamine and antibiotics. Other cell lines were 
maintained in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) plus antibiotics 
(Invitrogen, Carlsbad, CA). Antibodies for phospho-AKT serine 473 (sc-101629), Ki67 
(clone H-300, sc-15402) and proliferating cell nuclear antigen (PCNA, clone PC10, sc-56) 
were purchased from Santa Cruz Biotech (Santa Cruz, CA).
Animal Experiments, BrdU Labeling Assay and Immunohistochemistry
All animal studies were conducted under an approved Institutional Animal Care and Use 
Committee protocol. To determine the maximum tolerable dose (MTD) in animals, 5 group 
of nude mice (n = 3) were received intravenous (i.v.) injection of either BL05 dissolved in 
polypropylene glycol (PPG) or A10-conjugated BL05 loaded nano-micelles at 5 different 
doses (6.25, 12.5, 25, 50 and 100 mg/kg body weight). One additional group of animals 
were received the solvent PPG as control. Animals were monitored for 5 days for any sign 
of toxicity. No obvious evidence of side effects, including loss of appetite, loss of weight, 
reduced movement, sickness or death, was noticed. At necropsy, no macroscopic or 
microscopic sign or evidence for tissue/organ damage/bleeding or necrosis was observed in 
major organs, such as liver, spleen, lung, kidney, prostate, testis etc.
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For xenograft experiments in nude mice, we used four prostate cancer cell lines, androgen-
responsive LAPC-4 & LNCaP and castration-resistant C4-2 & 22RV1 to generate the 
subcutaneous xenografts. Cell suspension (2 × 106 cells in 0.1 ml of serum-free culture 
media) were inoculated subcutaneously (s.c.) into the rear flanks (2 sites/mouse) of 6-weeks-
old male nude mice (Charles River, Wilmington, MA). Once xenograft tumors were 
palpable (about 30 mm3 in size), animals were randomly divided into three groups (n = 8) 
and were treated with the solvent PPG (as the solvent control group), naked TGX221 pro-
drug BL05 in PPG (naked TGX221 group) and PSMA A10 aptamer-conjugated nanocarrier 
with BL05 (Nano-TGX221 group). The total volume of drug solution was 200 μl for tail 
vein injection twice a week and the TGX221 was used at a dose of 100 mg/kg bodyweight.
Tumor growth was monitored twice a week with a caliper. Tumor volume was calculated by 
the formula of L × W × H × 0.5236 (22) and tumor growth curve was generated by plotting 
the relative fold value of tumor volume at each time points comparing to their initial volume 
(set to value 1). The formula of calculation was ([Vtp – V0]/V0) × 100%; Vtp indicates tumor 
volume at each time-points; V0 indicates the initial volume at day 0 of treatment. In control 
group when the volume of xenograft tumors reached the limit of tumor burden set by our 
IACUC, animals were sacrificed and xenograft tumors were dissected. After tumor 
dissection, half of the tumor specimens were stored in -80C for further analysis and another 
half of the specimens were subjected for paraffin embedding process.
5-bromo-2-deoxyuridine (BrdU) labeling assay was conducted to label the newly 
synthesized DNA for evaluating tumor cell proliferation. At the end of experiments one hour 
before sacrifice, the animals were injected intraperitoneally (i.p.) with 0.5 ml of a 10-mM 
BrdU solution one hour before necropsy/sacrifice. To detect BrdU labeled cells in tissues, 
paraffin-embedded tissue sections were immunostained for incorporated BrdU using 
ZYMED BrdU Staining Kit (Invitrogen).
To detect apoptotic cell death in xenograft tumors, terminal deocynucleotide transferase 
dUTP nick end labeling (TUNEL) assay was conducted using Apo-BrdU-IHCTM in situ 
DNA Fragmentation Assay Kit (BioVision, Mountain View, CA), as described in our 
previous publication (23).
Immunostaining for anti-pAKT (S473), anti-Ki67 and anti-PCNA was conducted as 
described in our previous publication (23). Briefly, paraffin-embedded tissue sections were 
de-paraffinized and re-hydrated. Antigen recovery was achieved by boiling the sections in 
citrate acid buffer (10 mM, pH 6.0). The sections were incubated with the primary 
antibodies overnight at 4C and visualized using a DAKO LSAB+ Detection System (catalog 
#K0679, DAKO USA). The immunostaining results were expressed as a semi-quantitative 
index as described in our previous publication (24). Briefly, the intensity of the 
immunosignals was scored as 0 (negative), 1 (weak), 2 (moderate), and 3 (strong). The 
immunosignal index was calculated by multiplying the average intensity score with the 
percentage of positive cancer cells from at least 5 microscopic fields.
Tissue distribution of TGX221-loaded PSMA A10-nanomicelles was assessed by 
administering the formula at doses of 100, 50, 25, 12.5 and 6.25 mg/kg bodyweight in nude 
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mice bearing subcutaneous LNCaP xenografts (n = 3). Major organs (kidney, intestine, 
prostate, liver and spleen) and xenografts were excised after 5 days. For each tissue 
specimens, 15 mg of sample was digested with proteinase K, and the amount of TGX221 
was determined (μg/mg tissue) by HPLC as described in our initial publication (19).
RNA Extraction and Real-Time Reverse Transcription (RT)-PCR
Total tissue RNAs were prepared using Tri-Reagent (Invitrogen). To assess mRNA 
expression, a quantitative reverse transcription-PCR (qRT-PCR) assay was conducted using 
the SYBR Green-based approach on the Bio-Rad iQ5 system. The primer pairs for human 
PSA gene (forward 5′-ACCAGAGGAGTTCTTGACC CCAAA-3′; backward 5′-
CCCCAGAATCA CCCGAGCAG-3′) were described in our previous publication (25). 
Human KRT18 gene (forward 5′-CCAGTCTGTGGAGAACGACA-3′; backward 5′-
CTGGGCTTGTAGGCCTTTT AC-3′) was used as the internal control. The primers were 
synthesized by IDT (Coralville, IA). The qPCR counts were normalized against the value for 
the epithelial cell-specific gene KRT18 as described in our previous publication (25).
Statistical Analysis
Microscopic images of immunostaining results are presented from representative 
experiments. The mean and the standard error of the mean (SEM) were shown for tumor 
growth, BrdU labeling, TUNEL index, pAKT, Ki67, and PCNA immunostaining signal 
index, as well as qPCR data. The significance of differences between groups were analyzed 
by ANOVA analysis as described in our previous publications (12,23,25) using the SPSS 
computer software (SPSS, Inc., Chicago, IL).
Results
Nanomicellar TGX221 is mainly distributed within prostate cancer xenografts
In the initial phase of this project, we synthesized a TGX221 analog BL05 with a fatty acid 
modification (Fig 1A) so that the drug could be encapsulated into polymeric nanomicelle. 
The surface of the nanomicelle was conjugated with a RNA aptamer PSMA A10 to achieve 
prostate cancer-targeted delivery (26). The whole process of chemical synthesis and 
nanomicelle fabrication were described in our recent report (19). Then, the maximum 
tolerable dose and tissue distribution profile were determined in nude mice bearing 
xenograft tumors derived from prostate cancer LNCaP cell line. At the maximum dose of 
100 mg/kg bodyweight that was tested, no noticeable toxicity was observed at either gross 
observation or microscopic analysis of major organs (Fig 1B). Therefore, the dose of 100 
mg/kg bodyweight was used for the subsequent experiments. Tissue distribution assay 
revealed that after injection of naked or nanomicellar TGX221 (analog BL05), much higher 
levels of TGX221 (analog BL05) were detected in xenograft tumors, intestine, liver and 
prostate tissues than that in other organs (Fig 1C). The order of relative concentration of 
TGX221 in animals was as follow: xenograft > intestine > liver > prostate > spleen > 
kidney. This profile of tissue distribution suggested that the nanomicellar TGX221 
formulation is suitable for systemic delivery as an anti-cancer agent.
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Nanomicellar TGX221 completely blocks xenograft tumor growth in nude mice
Then, we tested the anti-tumor effect of the nanomicellar TGX221 formulation in mouse 
xenograft models. Four prostate cancer cell lines, androgen-responsive LAPC-4 and LNCaP 
as well as castration-resistant C4-2 and 22RV1, were used to establish s.c. xenograft tumors 
in nude mice. As shown in Fig 2, compared to the solvent control, treatment with 
nanomicellar TGX221 completely blocked xenograft tumor growth derived from all four 
cell lines. In contrast, treatment of animals with naked TGX221 without nanomicelle 
formulation only blocked tumor growth of xenografts derived from LAPC-4 and C4-2 cells 
(Fig 2A&2D) but not from LNCaP and 22RV1 cells although naked TGX221 suppressed 
xenograft tumor growth by 40-60% compared to the solvent control in these two xenograft 
models (Fig 2B&2C). These data indicated that nanomicellar TGX221 has a significant 
advantage over naked drug in blocking tumor growth of prostate cancers.
Nanomicellar TGX221 completely abolishes AKT phosphorylation and cell proliferation in 
xenograft tumor
After treatment, xenograft tumor specimens were dissected for immunohistochemical 
analysis of PI3K downstream protein AKT phosphorylation and cell proliferation index. As 
shown in Fig 3A, immunosignals for AKT phosphorylation were very strong in xenograft 
tumors from the control group. Treatment with naked TGX221 largely reduced the 
immunosignals of phosphor-AKT. These immunosignals were almost abolished in 
nanomicellar TGX221-treated xenograft tumors. Quantitative data were summarized in Fig 
3E.
Similarly, tumor cell proliferation indexes were assessed by detecting Ki67 and PCNA 
immunosignals as well as BrdU labeling in xenograft tissues. As shown in Fig 3B-3C, 
3F-3G and Fig 4A, these cell proliferation indexes were dramatically reduced in 
nanomicellar TGX221-treated xenograft tumors compared to the solvent control although 
naked TGX221-treated tumors also showed a significant lower index than that in the control 
group. These data are consistent with the tumor growth curve as measured by tumor size 
(Fig 2), indicating that nanomicellar TGX221 has a strong inhibitory effect in vivo on tumor 
cell proliferation by suppressing PI3K p110β-AKT signaling in prostate cancer.
Nanomicellar TGX221 induces apoptosis and reduces PSA gene expression in xenograft 
tumor
Next, we conducted a TUNEL assay to assess if nanomicellar TGX221 treatment induced 
apoptotic cell death in xenograft tumors. As shown in Fig 3D, clear positive immunosignals 
were visible on xenograft tumor sections treatment by nanomicellar TGX221 but it was less 
in naked TGX221-treated xenograft tumors. Quantitative analysis revealed a moderate 
apoptosis rate in nanomicellar TGX221-treated xenograft tumors but at a very low level in 
naked TGX221-treated tumor specimens (Fig 3H). These data indicate that apoptosis is not a 
major event in nanomicellar TGX221-induced suppression of xenograft tumor growth.
Lastly, we analyzed the prostate cancer specific gene PSA expression in xenograft tumor 
tissues by quantitative RT-PCR assays. As shown in Fig 4B, PSA gene expression at the 
mRNA level was significantly reduced in nanomicellar TGX221 treatment group as 
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compared to the naked drug or the solvent control groups. These data are consistent with our 
previous reports (12,23,27,28) that PI3K p110β activity is involved in androgen-stimulated 
gene expression.
Discussion
The goal of this study was to test the in vivo anti-tumor effect of nanomicellar TGX221 
formulation, a prostate cancer-targeted micelle loaded with the PI3K p110β-specific 
inhibitor TGX221. Tissue-specific targeting was achieved by conjugating micelle surface 
with a PSMA-binding RNA aptamer A10, as described in previous reports (19,29). We used 
four prostate cancer cell lines to establish s. c. xenograft models in nude mice for the in vivo 
testing. Animal treatment with the nanomicellar TGX221 did not show a noticeable toxicity 
even at a much higher dose level of 100 mg/kg body weight. Treatment with the 
nanomicellar TGX221 completely blocked xenograft tumor growth, which was largely 
effective than the naked drug solution. These anti-tumor effects were associated with 
reduced cell proliferation and AKT phosphorylation. Treatment with nanomicellar TGX221 
formulation also induced apoptotic cell death and reduced PSA gene expression.
Cellular PI3K family consists of multiple isoforms with diverse functions. It is predictable 
that non-specific inhibition of this major kinase family will result in multiple side effects 
when it is used in patients (30-32). Currently, multiple PI3K inhibitors are being tested in 
clinical trials for various human malignancies (33), of which two p110β-specific inhibitors 
GSK2636771 and SAR260301 are currently in phase I trials on solid tumors including 
prostate cancer. These two compounds have a slight similarity with TGX221 in molecular 
structure but SAR260301 has more drug-like properties including high water solubility and 
oral bioavailability (34). However, by taking the advantage of nanotechnology, nanomicelle 
conjugation of TGX221 greatly enhanced drug plasma concentration (19) and prostate 
cancer tumor tissue distribution in mice (Fig 1C). Although bleeding issues might be a 
clinical concern due to the critical role of p110β in blood platelet function (35), no obvious 
bleeding lesion was noticed grossly or microscopically on tissue sections from major organs 
of mice even after treatment with a MTD dose. These results indicate that prostate cancer 
cell-specific delivery of TGX221 with PSMA aptamer conjugation devoid of other 
cardiovascular actions.
As a unique cell surface protein, PSMA has been widely used as a biomarker in prostate 
cancer-targeted therapy and imaging (36). For example, we have successfully delivered 
PSMA-targeting RNA aptamer-conjugated poly(lactic-co-glycolic acid) (PLGA) 
nanoparticles to prostate cancer cells in a tissue-specific fashion (37). Similarly, in this 
study, the highest level of nanomicellar TGX221 accumulation was detected in prostate 
cancer tissues. Meanwhile, we also noticed that intestine and liver tissues had a relatively 
higher level of the drug (Fig 1C), which is consistent with previous reported that PSMA is 
also expressed in small intestine and liver tissues (38,39).
Recently, personalizing prostate cancer therapy has been emerging as a new trend of patient 
care due to heterogeneity of the disease (40,41). Alterations of PI3K-AKT-PTEN axis were 
reported in about 40-70% of primary and metastatic prostate cancers (41,42) and p110β has 
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been shown as a predominant factor for prostate cancer progression (12-15), therefore, the 
nanomicellar TGX221 might be used as a personalized therapy for p110β overactive patients 
due to gene overexpression or PTEN-loss mutation. However, a reciprocal feedback 
regulation of PI3K pathway and the AR signaling was determined in prostate cancer animal 
models (43); the nanomicellar TGX221 formulation might be used together with an effective 
anti-AR therapy like Enzalutamide to overcome any potential resistance.
In conclusion, we demonstrated that nanomicellar TGX221 was effective in blocking tumor 
growth of prostate cancer xenografts in nude mice. This anti-tumor effect was associated 
with reduced AKT phosphorylation and tumor cell proliferation. Our data suggest that the 
nanomicellar TGX221 formulation might be used as one component of personalized 
medicine for prostate cancer patients who are harboring alterations in PI3K pathway.
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EPR enhanced permeability and retention
FBS fetal bovine serum
FDA federal drug&food administration
MTD maximum tolerable dose
Nano nanometer





PSA prostate specific antigen
PSMA prostate membrane specific antigen
RES reticular endothelial system
SEM standard error of the MEAN
TUNEL terminal deocynucleotide transferase dUTP nick end labeling
US FDA United States Food and Drug Administration
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A Scheme of the molecular structure of TGX221 and its analog BL05, as well as 
nanomicellar TGX221-BL05 formulation. Circled in red line indicates the modified position 
on TGX221 for conjugation with micelle polymers. Scale bar, 50 nm.
B Microscopic images of mice organs. Mice were treated with the solvent (PPG, 200 μl), 
TGX221-BL05 in polypropylene glycol (PPG) solution (naked TGX221) and nanomicellar 
TGX221 formulation (nano-TGX221). Drugs were injected via tail vein at a dose of 100 
mg/kg bodyweight in 200 μl PPG solution. Animals were sacrificed at day 5 after drug 
delivery and the major organs as indicated on the left side of the panels were dissected for 
histological analysis after H&E staining. Magnification, × 200.
C. Tissue distribution of the delivered drug TGX221. Mice tissues harvested at autopsy 
described in panel B were homogenized for quantitative measurement of the TGX221 
compound. Data were presented as Mean (n = 3) and error bars indicate the SEM. The 
asterisk indicates significant difference compared to the naked drug (P < 0.05, Student t-
test).
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Systemic delivery of TGX221 suppresses xenograft tumor growth derived from prostate 
cancer cells in nude mice. Xenografts were established from prostate cancer LAPC-4 (A), 
LNCaP (B), 22RV1 (C) and C4-2 (D) cells. Once xenograft tumors were palpable, animals 
were randomized into three groups (n = 8) and treated with intravenous injection of the PPG 
solution (solvent control), TGX221-BL05 dissolved in PPG (naked TGX221) or 
nanomicellar TGX221-BL05 (nano-TGX221). Drugs were used at a dose of 100 mg/Kg 
body weight in 200 μl volume via tail vein twice a week for 3 weeks. Tumor sizes were 
monitored at each treatment and presented as a percentage value at the measurement 
compared to the size on the first day of treatment. Data were presented as the Mean and 
error bars indicate the SEM. The asterisk and pone signs indicate significant differences 
compared to the control group (ANOVA analysis, * P < 0.01, # P < 0.05).
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A-D TGX221 suppresses AKT phosphorylation (A), reduces cell proliferation (B, Ki67; C, 
PCNA) and induces apoptosis (D, TUNEL). Paraffin-embedded tissue sections from 
harvested xenografts after treatment indicated on the left side of the panel (as described in 
Fig 2) were used for the immunostaining with antibodies listed on each panels. 
Representative microscopic images were shown for the immunostaining results. 
Magnification, × 200.
E-H Quantitative data from each immunostaining assays were summarized as average value 
(MEAN) of the immnosignal indexes as described (24). Error bars indicate the SEM of the 
MEAN. The asterisks indicate significant differences compared to the solvent control (P < 
0.05, Student t-test).
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TGX221 treatment reduces cellular BrdU labeling (A) and PSA gene expression (B) in 
prostate cancer xenograft tumors in nude mice.
A BrdU labeling assay was conducted at the end of drug treatment with intraperitoneal 
injection of 100 μl BrdU solution as described in our previous publication (24). After tissue 
harvesting, paraffin-embedded sections were used for anti-BrdU immunostaining and the 
average (MEAN) of the quantitated immunosignals indexes as described (24) were shown in 
each xenograft tumor group.
B Total RNA samples were extracted form tissue specimens of xenograft tumors harvested 
from animals after drug treatment. Quantitative RT-PCR assays were conducted to examine 
PSA gene expression at the mRNA levels and the relative levels of PSA gene expression 
from each group (n = 8) were presented as the MEAN. Error bars represent the SEM of the 
MEAN and the asterisk indicates a significant difference compared to the Solvent control 
(Student t-test, P < 0.05).
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